Skip to main content

54 - References

References

Prescribing in children and adolescents CHAPTER 5 References

  1. Kendrick JG, et al. Pharmacologic management of agitation and aggression in a pediatric emergency department – a retrospective cohort study. J Pediatric Pharmacol Therapeutics 2018; 23:­455–­459.
  2. Wolpert KH, et al. Behavioral management of children with autism in the emergency department. Pediatr Emerg Care 2023; 39:­45–­50.
  3. National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. Clinical Guidance [CG155]. 2013 (last updated October 2016, last checked October 2023); https://www.nice.org.uk/guidance/cg155.
  4. Chang MY, et al. Drug-­induced extrapyramidal symptoms at the pediatric emergency department. Pediatr Emerg Care 2020; 36:­468–­472.
  5. National Institute for Health and Care Excellence. Violence and aggression: short-­term management in mental health, health and community settings. NICE Guideline [NG10]. 2015 (last checked October 2023); https://www.nice.org.uk/guidance/ng10.
  6. Rudolf F, et al. A retrospective review of antipsychotic medications administered to psychiatric patients in a tertiary care pediatric emergency department. J Pediatric Pharmacol Therapeutics 2019; 24:­234–­237.
  7. Cole JB, et al. The use, safety, and efficacy of olanzapine in a level I pediatric trauma center emergency department over a 10-­year period. Pediatr Emerg Care 2020; 36:­70–­76.
  8. Breier A, et al. A double-­blind, placebo-­controlled dose-­response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59:­441–­448.
  9. Lindborg SR, et al. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res 2003; 119:­113–­123.
  10. Powney MJ, et al. Haloperidol for psychosis-­induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2012; 11:CD009377.
  11. TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 2003; 327:­708–­713.
  12. Nobay F, et al. A prospective, double-­blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med 2004; 11:­744–­749.
  13. Schwagmeier R, et  al. Midazolam pharmacokinetics following intravenous and buccal administration. Br J Clin Pharmacol 1998; 46:­203–­206.
  14. Taylor D, et al. Buccal midazolam for agitation on psychiatric intensive care wards. Int J Psychiatry Clin Pract 2008; 12:­309–­311.
  15. Nunn K, et al. Medication table. In: Nunn KP, Dey C, eds. The Clinician’s Guide to Psychotropic Prescribing in Children and Adolescents, 1st edn. Sydney: Glad Publishing 2003:­383–­452.
  16. Khan SS, et al. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. J Child Adolesc Psychopharmacol 2006; 16:­671–­677.
  17. Staller JA. Intramuscular ziprasidone in youth: a retrospective chart review. J Child Adolesc Psychopharmacol 2004; 14:­590–­592.
  18. Sanford M, et al. Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs 2008; 22:­335–­352.
  19. National Institute for Health and Clinical Excellence. Aripiprazole for schizophrenia in people aged 15 to 17 years. Technology Appraisal [TA213]. 2011 (last checked October 2023); https://www.nice.org.uk/guidance/ta213.
  20. Lesem MD, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-­controlled study of inhaled loxapine. Br J Psychiatry 2011; 198:­51–­58.

No comments to display

Back to top